Skip to main content

Kennedy's Disease

1
Pipeline Programs
1
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

AnnJi Pharmaceutical
AnnJi PharmaceuticalTaiwan - Taipei City
1 program
1
AJ201Phase 1/22 trials
Active Trials
NCT07549919Recruiting26Est. Apr 2026
NCT05517603Completed25Est. Apr 2024

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
AnnJi PharmaceuticalAJ201
AnnJi PharmaceuticalAJ201

Clinical Trials (2)

Total enrollment: 51 patients across 2 trials

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients

Start: Feb 2023Est. completion: Apr 202425 patients
Phase 1/2Completed

A Study to Evaluate the Effect of Food on the Bioavailability of AJ201, and Safety, Tolerability, and Pharmacokinetics of AJ201 in Japanese and White Healthy Male Participants

Start: Apr 2026Est. completion: Apr 202626 patients
Phase 1Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 51 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.